Vaxcyte Inc (NAS:PCVX)

Q4 2025 Vaxcyte Inc Earnings Call Transcript

Feb 24, 2026 / 09:30 PM GMT

Release Date Price: $61.35 (+1.81%)

Transcript 10-K8-K

Key Points

Positve

Vaxcyte Inc (PCVX) reported unprecedented results from their phase 2 study in adults, indicating that VAX 31 may offer substantial improvement over existing pneumococcal vaccines.
The company has initiated multiple phase 3 trials, including Opus 1, Opus 2, and Opus 3, to further evaluate the safety, tolerability, and immunogenicity of VAX 31.
Vaxcyte Inc (PCVX) completed the construction of a dedicated large-scale manufacturing facility on time and on budget, designed to support global commercial demand.
The company strengthened its financial position with a successful public equity offering, raising approximately $600.2 million, providing a cash runway through at least the end of 2028.
Vaxcyte Inc (PCVX) resumed development of their Group A strep vaccine candidate, VAX A1, with plans to initiate a phase 1 study in adults this year.

Negative

Despite progress, gaps in serotype coverage persist in current vaccines, highlighting the ongoing challenge of achieving broader spectrum protection.
The company anticipates increased expenses in 2026, particularly within R&D, driven by manufacturing readiness and clinical trial expansions.
There is a risk of not achieving perfection in serotype comparisons, as acknowledged by the FDA, which could impact the approval process.
The competitive landscape includes other companies like GSK and Pfizer, which are also developing broader spectrum pneumococcal vaccines.
The company faces challenges in demonstrating the ability to improve immune responses in previously vaccinated adults, which is crucial for obtaining a catch-up recommendation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PCVX.OQ - Vaxcyte Inc
Q4 2025 Vaxcyte Inc Earnings Call
Feb 24, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. My name is Chloe, and I will be your conference operator for the Vacsite 4th quarter and full year 2025 financial results conference call.

All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period.

If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad.

If you would like to withdraw your question, press 2.

Today's call is being recorded. I will now turn the call over to Andrew Guggenheim, President and Chief Financial Officer of Vacite. Please go ahead, sir.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.